Humanin; A defender against Alzheimer's disease?

Recent Patents on CNS Drug Discovery

Volumn 4, Issue 1, 2009, Pages 37-42

  Matsuoka, Masaaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

A ; Alzheimer's disease; Humanin; Neuronal death; Neuronal dysfunction

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; CHOLINE ACETYLTRANSFERASE; HUMANIN; MUSCARINIC RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; PLACEBO; RATTIN; TARENFLURBIL; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VESICULAR ACETYLCHOLINE TRANSPORTER; AMYLOID PRECURSOR PROTEIN; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; BRAIN CORTEX; CELL DEATH; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXPRESSION VECTOR; HIPPOCAMPUS; HUMAN; IMMUNOBLOTTING; MENINGOENCEPHALITIS; NERVE CELL MEMBRANE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; TISSUE LEVEL; UPREGULATION; VACCINATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NERVE CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL DEATH; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURONS;

EID: 62249218290     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488909787002609     Document Type: Review

References (60)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
2. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
3. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44: 181-193.
4. Marx J. Alzheimer's disease. Fresh evidence points to an old suspect: Calcium Science 2007; 318: 384-385.
5. Bojarski L, Herms J, Kuznicki J. Calcium dysregulation in Alzheimer's disease. Neurochem Int 2008; 52: 621-633.
6. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
7. Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, Dunaevsky A. Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 2006; 33: 274-282.
8. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMD-Atype glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866-2875.
9. Knobloch M, Man IM. Dendritic spine loss and synaptic alterations in Alzheimer's disease. Mol Neurobiol 2008; 37: 73-82
10. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
11. Müller T, Meyer HE, Egensperger R, Marcus K. The amyloid precursor protein intracellular domain (AICD] as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog Neurobiol 2008; 85(4): 393-406.
12. Kawasumi M, Matsuda S, Matsuoka M, Nishimoto I. Cytoplasmic tail adaptors of Alzheimer's amyloid-beta protein precursor. Mol Neurobiol 2004; 30: 185-200.
13. Nevé RL, McPhie DL, Chen Y. Alzheimer's disease: A dysfunction of the amyloid precursor protein. Brain Res 2000; 886: 54-66.
14. Niikura T, Hashimoto Y, Tajima H, Nishimoto I. Death and survival of neuronal cells exposed to Alzheimer's insults. J Neurosci Res 2002; 70: 380-391.
15. Lu DC, Rabizadeh S, Chandra S, et al. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med 2000; 6: 397-404.
16. Galvan V, Gorostiza OF, Banwait S, et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci 2006; 103: 7130-7135.
17. Saganich MJ, Schroeder BE, Galvan V, Bredesen DE, Koo EH, Heinemann SF. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J Neurosci 2006; 26: 13428-13436.
18. Morrison JH, Hof PR. Life and death of neurons in the aging cerebral cortex. Int Rev Neurobiol 2007; 81: 41-57.
19. Desikan RS, Fischl B, Cabral HJ, et al. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology 2008; 71(11): 819-25.
20. Ohno M, Cole SL, Yasvoina M, et al. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis 2007; 26: 134-145.
21. Shen Y, He P, Zhong Z, McAllister C, Lindholm K. Distinct destructive signal pathways of neuronal death in Alzheimer's disease. Trends Mol Med 2006; 12: 574-579.
22. Zhao B, Chrest FJ, Horton WE Jr., Sisodia SS, Kusiak JW. Expression of mutant amyloid precursor proteins induces apoptosis in PC12 cells. J Neurosci Res 1997; 47: 253-263.
23. Luo JJ, Wallace W, Riccioni T, Ingram DK, Roth GS, Kusiak JW. Death of PC12 cells and hippocampal neurons induced by adenoviral-mediated FAD human amyloid precursor protein gene expression. J Neurosci Res 1999; 55: 629-642.
24. Yamatsuji T, Okamoto T, Takeda S, et al. G protein-mediated neuronal DNA fragmentation by familial Alzheimer's disease associated V642 mutants of APP. Science 1996; 272: 1349-1352.
25. Hashimoto Y, Niikura T, Ito Y, Nishimoto I. Multiple mechanisms underlie neurotoxicity by different types of Alzheimer's disease mutations of amyloid precursor protein. J Biol Chem 2000; 275: 34541-34551.
26. Chen Y, Liu W, McPhie DL, Hassinger L, Neve RL. APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. J Cell Biol 2003; 163: 27-33.
27. McPhie DL, Coopersmith R, Hines-Peralta A, et al. DNA synthesis and neuronal apoptosis caused by familial Alzheimer's disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci 2003; 23: 6914-6927.
28. Matsuoka M, Hashimoto Y, Aiso S, Nishimoto I. Humanin and colivelin: Neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis. CNS Drug Rev 2006; 12: 113-122.
29. Laifenfeld D, Patzek LJ, McPhie DL, et al. Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis. J Neurosci 2007; 27: 7141-7153.
30. Sudo H, Jiang H, Yasukawa T, et al. Antibody-regulated neurotoxic function of cell-surface beta-amyloid precursor protein. Mol Cell Neurosci 2000; 16: 708-723.
31. Hashimoto Y, Chiba T, Yamada M, et al. Transforming growth factor beta2 is a neuronal death-inducing ligand for amyloid-beta precursor protein. Mol Cell Biol 2005; 25: 9304-9317.
32. Hashimoto Y, Nawa M, Chiba T, Aiso S, Nishimoto I, Matsuoka M. Transforming growth factor beta2 autocrinally mediates neuronal cell death induced by amyloid-beta. J Neurosci Res 2006; 83: 1039-1047.
33. Gilman S, Koller M, Black RS, et al. For the AN1792(QS-21)-201 Study Team Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial Neurology 2005; 64: 1553-1562.
34. Wisniewski T, Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol 2000; 7(9): 805-11 In press.
35. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223.
36. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Tarenflurbil phase II study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: A randomised phase II trial. Lancet Neurol 2008; 7: 483-493.
37. Miners JS, Baig S, Palmer J, et al. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008; 18; 240-252.
38. Hashimoto Y, Niikura T, Tajima H, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and A. Proc Natl Acad Sci USA 2001; 98: 6336-6341.
39. Hashimoto Y, Niikura T, Ito Y, et al. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults. J Neurosci 2001; 21: 9235-9245.
40. Nishimoto, I.: US20087314864 (2008).
41. Nishimoto I, Matsuoka M, Niikura T. Unravelling the role of Humanin. Trends Mol Med 2004; 10: 102-105.
42. Caricasole A, Bruno V, Cappuccio I, Melchiorri D, Copani A, Nicoletti F. A novel rat gene encoding a Humanin-like peptide endowed with broad neuroprotective activity. FASEB J 2002; 16: 1331-1333.
43. Kariya S, Takahashi N, Ooba N, Kawahara M, Nakayama H, Ueno S. Humanin inhibits cell death of serum-deprived PC12h cells. Neuroreport 2002; 13: 903-907.
44. Kariya S, Hirano M, Nagai Y, et al. Humanin attenuates apoptosis induced by DRPLA proteins with expanded polyglutamine stretches. J Mol Neurosci 2005; 25: 165-169.
45. Xu X, Chua CC, Gao J, Hamdy RC, Chua BH. Humanin is a novel neuroprotective agent against stroke. Stroke 2006; 37: 2613-2619.
46. Xu X, Chua CC, Gao J, et al. Neuroprotective effect of humanin on cerebral ischemia/reperfusion injury is mediated by a PI3K/Akt pathway. Brain Res 2008; 1227: 12-8.
47. Chiba T, Yamada M, Hashimoto Y, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: Characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci 2005; 25: 10252-10261.
48. Yamagishi Y, Hashimoto Y, Niikura T, Nishimoto I. Identification of essential amino acids in Humanin, a neuroprotective factor against Alzheimer's disease-relevant insults. Peptides 2003; 24: 585-595.
49. Guo B, Zhai D, Cabezas E, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003; 2423: 456-461.
50. Ying G, Iribarren P, Zhou Y, et al. Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J Immunol 2004; 172: 7078-7085.
51. Villegas, S., Kelner, G.S., Unett, D.J., Gatlin, J.: US20080125491 ( 2008).
52. Hashimoto Y, Suzuki H, Aiso S, Niikura T, Nishimoto I, Matsuoka M. Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection. Life Sci 2005; 77: 3092-3104.
53. Matsuoka, M.; Nishimoto, I.; Aiso, S.: EP1878745 (2008).
54. Mamiya T, Ukai M. [Gly(14]]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br J Pharmacol 2001; 134: 1597-1599.
55. Tajima H, Kawasumi M, Chiba T, et al. A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice. J Neurosci Res 2005; 79: 714-723.
56. Krejcova G, Patocka J, Slaninova J. Effect of humanin analogues on experimentally induced impairment of spatial memory in rats. J Pept Sci 2004; 10: 636-639.
57. Yamada M, Chiba T, Sasabe J, Terashita K, Aiso S, Matsuoka M Nasal colivelin treatment ameliorates memory impairment related to Alzheimer's disease. Neuropsychopharmacology 2008; 33: 2020-2032.
58. Kunešová G, Hlavácček J, Patočka J, et al. The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues. Peptides 2008; in press.
59. Matsuoka, M., Nishimoto, S., Aiiso, S.: JP2008019245 (2008).
60. Chiba T, Kita Y, Matsuoka M, et al. IPC8 Class: AA61K3816FI USPC Class: 514 12.